Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

Safety And Effectiveness Of NaviFUS System With Bevacizumab In Recurrent Glioblastoma

NCT: NCT07274787 · NOT_YET_RECRUITING

NCT IDNCT07274787
StatusNOT_YET_RECRUITING
Start Date2026-12-01
Completion2029-12-01
SponsorUniversity of Cincinnati (OTHER)
First posted
Last updated

Brief Summary

This study will evaluate the safety and early effectiveness of the NaviFUS system with concomitant microbubble administration in conjunction with BEV in recurrent GBM patients.

Frequently Asked Questions

What is Safety And Effectiveness Of NaviFUS System With Bevacizumab In Recurrent Glioblastoma?

Safety And Effectiveness Of NaviFUS System With Bevacizumab In Recurrent Glioblastoma is a clinical trial registered under NCT07274787. Current status: NOT_YET_RECRUITING.

What is the status of NCT07274787?

The current status of NCT07274787 (Safety And Effectiveness Of NaviFUS System With Bevacizumab In Recurrent Glioblastoma) is: NOT_YET_RECRUITING.

When did Safety And Effectiveness Of NaviFUS System With Bevacizumab In Recurrent Glioblastoma start?

Safety And Effectiveness Of NaviFUS System With Bevacizumab In Recurrent Glioblastoma started on 2026-12-01.

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.

↑